Primary Biliary Cholangitis Trial, Recruiting (NCT07449793)

Primary Biliary Cholangitis Trial, Recruiting NCT07449793 Sponsor: RenJi Hospital Condition: Primary Biliary Cholangitis

Printed from Voxsanity (voxsanity.com.au) — NCT07449793 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Primary Biliary Cholangitis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are 18 years of age or older, either male or female
You have been diagnosed with a liver condition called Primary Biliary Cholangitis (PBC), based on specific medical guidelines from 2018
You are currently taking a medication called UDCA (ursodeoxycholic acid) at a standard daily dose, with or without other additional treatments

Who may not be able to join:

You have another liver disease at the same time, such as Hepatitis C, or an active Hepatitis B infection (certain Hepatitis B cases may still be considered — confirm with trial site)
You have a liver condition called Autoimmune Hepatitis (AIH) or Primary Sclerosing Cholangitis (PSC)
You have been diagnosed with, or are suspected of having, liver cancer (hepatocellular carcinoma)
You are currently pregnant or breastfeeding
You have a history of other cancers, including blood cancers or solid tumours in other parts of the body (outside the liver and bile system)
You are unable or unlikely to attend all required follow-up appointments throughout the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Xiong Ma, MD, PhD, RenJi Hospital

Phone: +8615800744783

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07449793

Sponsor: RenJi Hospital

Phase: Not Applicable

Status: Recruiting

Condition: Primary Biliary Cholangitis

Trial contact: +8615800744783

More information: https://clinicaltrials.gov/study/NCT07449793

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are 18 years of age or older, either male or female
You have been diagnosed with a liver condition called Primary Biliary Cholangitis (PBC), based on specific medical guidelines from 2018
You are currently taking a medication called UDCA (ursodeoxycholic acid) at a standard daily dose, with or without other additional treatments

Who may not be able to join:

You have another liver disease at the same time, such as Hepatitis C, or an active Hepatitis B infection (certain Hepatitis B cases may still be considered — confirm with trial site)
You have a liver condition called Autoimmune Hepatitis (AIH) or Primary Sclerosing Cholangitis (PSC)
You have been diagnosed with, or are suspected of having, liver cancer (hepatocellular carcinoma)
You are currently pregnant or breastfeeding
You have a history of other cancers, including blood cancers or solid tumours in other parts of the body (outside the liver and bile system)
You are unable or unlikely to attend all required follow-up appointments throughout the study

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

RenJi Hospital

Registry

ClinicalTrials.gov

Start date

1 February 2026

Est. completion

31 July 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Rate of complication-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov